Doxepin intranasal - Winston Pharmaceuticals

Drug Profile

Doxepin intranasal - Winston Pharmaceuticals

Alternative Names: Dolorac

Latest Information Update: 08 Aug 2015

Price : $50

At a glance

  • Originator Winston Pharmaceuticals
  • Class Antipruritics; Dibenzoxepins; Oxepins; Sleep disorder therapies; Small molecules; Tricyclic antidepressants
  • Mechanism of Action Histamine H1 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Headache

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 08 Aug 2015 Phase II development is ongoing in the USA
  • 23 Nov 2010 Final efficacy data from a phase IIa trial in Headache released by Winston Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top